SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-037456
Filing Date
2024-04-30
Accepted
2024-04-30 07:35:40
Documents
15
Period of Report
2024-04-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0204809-8k_virpax.htm   iXBRL 8-K 27013
2 PRESS RELEASE OF VIRPAX PHARMACEUTICALS, INC., DATED APRIL 29, 2024 ea020480901ex99-1_virpax.htm EX-99.1 17503
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2465
  Complete submission text file 0001213900-24-037456.txt   229146

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE vrpx-20240430.xsd EX-101.SCH 3027
5 XBRL LABEL FILE vrpx-20240430_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE vrpx-20240430_pre.xml EX-101.PRE 22367
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0204809-8k_virpax_htm.xml XML 3804
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 24894060
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)